CONGRESS MATERIALS

Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
John Teeter, Robert Charnigo, Nandini Cossons, Sangeeta Raje, Eunhee Hwang, Thomas Le Duigou August 25, 2022 NHF 2022 Hemophilia

Safety and Efficacy of Marstacimab for Prevention of Bleeding Episodes in Pediatric Patients With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B With or Without Inhibitors

View Presentation
Poster
Debra D Pittman, Charles Carrieri, Holly Soares, John McKay, Charles Tan, John Liang, Swapnil Rakhe, Jean-Claude Marshall, John Murphy, Jeremy Rupon August 26, 2022 NHF 2022 Hemophilia

Preliminary Field Study Results Suggest Differences in FIX Activity Based on Assay From Gene Therapy Trial Patients Expressing R338L High-Activity Variant of FIX

View Presentation